WM-8014
Based on 3 publication(s) in Google Scholar
WM-8014 is an inhibitor of MOZ, a member of histone acetyltransferases, with an IC50 of 55 nM.
For research use only. We do not sell to patients.
- Purity: 99.92%
- CAS No.: 2055397-18-5
- Formula: C20H17FN2O3S
- Molecular Weight:384.42
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Epigenetics Compound Library
HY-L005
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Targeted Diversity Library
HY-L099
-
Bioactive Compound Library Max
HY-L181
-
Epigenetics Compound Library Mini
HY-L005M
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) WM-8014
More
Customer Validation & Images
-
Histological Imaging/Staining
-
Histological Imaging/Staining
-
WB
-
IF
-
Bio/Physico-chemical Assay
Biological Activity
|
MOZ/MORF |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Sf9 | IC50 |
0.028 μM
Compound: 97; WM-8014
|
Inhibition of N-terminal GST-tagged recombinant human KAT6B (431 to end residues) expressed in baculovirus infected Sf9 insect cells using acetyl coenzyme A and N-terminal histone H4 peptide (sequence SGRGKGGKGLGKGGAKRHRKV-GGK-biotin) as substrate incubat
Inhibition of N-terminal GST-tagged recombinant human KAT6B (431 to end residues) expressed in baculovirus infected Sf9 insect cells using acetyl coenzyme A and N-terminal histone H4 peptide (sequence SGRGKGGKGLGKGGAKRHRKV-GGK-biotin) as substrate incubat
|
[PMID: 31256587] |
WM-8014 (Compound 36) is an inhibitor of MOZ, with an IC50 of 55 nM. WM-8014 causes cell senescence and suppresses the proliferation with IC50s of 1.6 μM and 551 nM, respectively. WM-8014 also reduces mRNA coding for the MOZ gene Cdc6 by 65.1%[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2055397-18-5
-
Appearance Solid
-
Molecular Weight 384.42
-
Formula C20H17FN2O3S
-
Color White to off-white
-
SMILES
O=C(C1=CC(C2=CC=CC=C2)=CC(C)=C1F)NNS(=O)(C3=CC=CC=C3)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cancer Discov
KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs. [Abstract]2022 Mar 1;12(3):792-811. PMID: 34853079
WM-8014 purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2022 Mar 1;12(3):792-811. [Abstract]
Surface expression of CD11b after 4 days treatment of WM-8014 (10 μM) in MOLM-13 and RN2 cells.
-
Am J Physiol Cell Physiol
2025 Jul 1;329(1):C38-C49. PMID: 40434042
WM-8014 purchased from MedChemExpress. Usage Cited in: Am J Physiol Cell Physiol. 2025 Jul 1;329(1):C38-C49. [Abstract]
Histological analysis showed that ovaries in the WM-8014 (10 μM, 4 days) group had fewer activated follicles than those in the control group.
WM-8014 purchased from MedChemExpress. Usage Cited in: Am J Physiol Cell Physiol. 2025 Jul 1;329(1):C38-C49. [Abstract]
Follicle counting results showed that the inhibition of KAT6A by WM-8014 (10 μM, 4 days) inhibited primordial follicle activation. PF represents primary follicle, PmF represents primordial follicle.
WM-8014 purchased from MedChemExpress. Usage Cited in: Am J Physiol Cell Physiol. 2025 Jul 1;329(1):C38-C49. [Abstract]
Western blotting results of the mTOR signaling pathway after ovaries were treated with WM-8014 (10 μM, 3 days) or CTX-648. n = 6 biologically independent samples, and the experiment was repeated three times.
WM-8014 purchased from MedChemExpress. Usage Cited in: Am J Physiol Cell Physiol. 2025 Jul 1;329(1):C38-C49. [Abstract]
Immunostaining showed that the cytoplasmic localization of FOXO3a (CL-FOXO3a) decreased in primordial follicles after treatment with WM-8014 (10 μM, 3 days).
-
Solvent & Solubility
DMSO : ≥ 250 mg/mL (650.33 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
To determine the inhibition of Moz activity by the test compounds, assay reactions are conducted in a volume of 8 μL in 384-well low volume assay plates. The reactions are performed in assay buffer (100 mM Tris-HCl, pH 7.8, 15 mM NaCl, 1 mM EDTA, 0.01% Tween-20, 1 mM Dithiothreitol, and 0.02% m/v chicken egg white albumin). Reactions are set up with 0.4 μM Acetyl coenzyme A (AcCoA), 50 nM N-terminal histone H4 peptide (sequence SGRGKGGKGLGKGGAKRHRKV-GGK-biotin), 10 nM MOZ enzyme, and an acetyl-lysine specific antibody (final dilution 1: 10000). 11-point dilution series of the compounds (WM-8014) of the invention are prepared in DMSO; a volume of 100 nL is transferred using a pin tool into assay plates containing substrates, before adding enzyme to start the reaction. Positive (no compound) and negative (AcCoA omitted) control reactions are included on the same plates and receive the same amount of DMSO as the compound treated wells. After adding all reagents, the plates are sealed with adhesive seals and incubated for 90 minutes at room temperature[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6013 mL | 13.0066 mL | 26.0132 mL | 65.0330 mL |
| 5 mM | 0.5203 mL | 2.6013 mL | 5.2026 mL | 13.0066 mL | |
| 10 mM | 0.2601 mL | 1.3007 mL | 2.6013 mL | 6.5033 mL | |
| 15 mM | 0.1734 mL | 0.8671 mL | 1.7342 mL | 4.3355 mL | |
| 20 mM | 0.1301 mL | 0.6503 mL | 1.3007 mL | 3.2517 mL | |
| 25 mM | 0.1041 mL | 0.5203 mL | 1.0405 mL | 2.6013 mL | |
| 30 mM | 0.0867 mL | 0.4336 mL | 0.8671 mL | 2.1678 mL | |
| 40 mM | 0.0650 mL | 0.3252 mL | 0.6503 mL | 1.6258 mL | |
| 50 mM | 0.0520 mL | 0.2601 mL | 0.5203 mL | 1.3007 mL | |
| 60 mM | 0.0434 mL | 0.2168 mL | 0.4336 mL | 1.0839 mL | |
| 80 mM | 0.0325 mL | 0.1626 mL | 0.3252 mL | 0.8129 mL | |
| 100 mM | 0.0260 mL | 0.1301 mL | 0.2601 mL | 0.6503 mL |
Powered by Bioz